Oxford Urology Associates Oxford Urology Associates
Many people think of erectile dysfunction (ED) as a sexual issue, but that is not always the case. Facts suggest there is a link between erectile dysfunction and other medical conditions including cardiac disease. In fact, ED may be one of the first signs of cardiovascular problems for men.
Continue reading “The Link Between Erectile Dysfunction And Cardiac Disease”
Oxford Urology Associates is proud to announce that Dr. Land Renfroe is the first physician in the state of Mississippi to treat patients with new medical technology from Medtronic to treat people suffering from urinary and fecal incontinence.
Continue reading “Dr. Renfroe First M.S. Physician To Treat Patients With InterStim II System”
Attention patients: If you or any of your family members are suffering from cold or flu-like symptoms, please call Oxford Urology Associates at (662) 234-1448 before your scheduled appointment. Our patient’s health is our number one priority.
Oxford Urology Associates is extremely proud to announce that Dr. Land Renfroe’s Medtronic InterStim program has been officially designated as an InterStim Center of Excellence (COE). The COE recognizes physicians who demonstrate exemplary use of the InterStim System and a commitment to patient care for those suffering from symptoms associated with Overactive Bladder, Fecal Incontinence and Non-Obstructive Urinary Retention.
The Medtronic COE program is designed to helppatients find experienced physicians who show exemplary care with the InterStim system while also recognizing physicians for their exemplary care.
Dr. Renfroe is the FIRST and ONLY physician in Mississippi to be designated with the Medtronic InterStim COE. We are very proud to provide the highest quality of care for those in the state of Mississippi.
Please call us at (662) 262-1050 to schedule your appointment with Dr. Renfroe if you or a loved one is suffering from urinary and or bowel control problems!
For more information on the Medtronic InterStim COE, please visit Medtronic’s website here.
Our office has recently changed to a new computer system and over the past couple of weeks experienced a glitch that sent out statements that were from old visits or duplicated. Please disregard those. We will need you to call our office or mail back the statements you received so that we can correct your account and you will no longer receive the incorrect statements. We appreciate your patience and understanding while we work to correct this issue.
Can you believe we’re approaching the end of the year already? In November and December, our office will be closed on a few select days so that our staff can enjoy the holidays with family and friends. Continue reading “Holiday Hours”
Oxford Urology is proud to be a sponsor for Bid for the Kids Charity Ball on December 8, 2018.
All proceeds from the event will go toward the Junior Auxiliary of Oxford’s projects for children in Oxford and Lafayette County.
Oxford Urology Associates today announced that Dr. Brent Hardin has been designated as a UroLift® Center of Excellence. The designation recognizes that Dr. Hardin has achieved a high level of training and experience with the UroLift System and demonstrated a commitment to exemplary care for men suffering from symptoms associated with Benign Prostatic Hyperplasia or BPH. Dr. Hardin has treated more than 450 patients using the UroLift System.
“The UroLift System has fundamentally changed how I treat men in my practice who have symptoms associated with BPH,” said Dr. Hardin. “Patients are experiencing rapid symptom relief and are often able to discontinue the use of ongoing BPH medications. It won’t be long before the UroLift System becomes the standard of care for treating BPH patients.”
Nearly 40 million men in the United States are affected by BPH. Not to be confused with prostate cancer, BPH occurs when the prostate gland that surrounds the male urethra becomes enlarged with advancing age and begins to obstruct the urinary system. Symptoms of BPH often include interrupted sleep and urinary problems, and can cause loss of productivity, depression and decreased quality of life.
Five-year data from a randomized study shows the UroLift System offers not only rapid improvement but also durable relief for patients with BPH. After five years, patients treated with the UroLift System continue to experience symptom relief with minimal side effects, with few patients requiring an additional procedure for relief. A second randomized clinical trial called BPH6 demonstrated that the minimally invasive UroLift System compares very well to the reference standard surgery, transurethral resection of the prostate (TURP), with regard to efficacy, and is superior to TURP at preserving sexual function and offering a more rapid recovery.
Medication is often the first-line therapy for enlarged prostate, but relief can be inadequate and temporary. Side effects of medication treatment can include sexual dysfunction, dizziness and headaches, prompting many patients to quit using the drugs. For these patients, the classic alternative is surgery that cuts, heats or removes prostate tissue to open the blocked urethra. While current surgical options can be very effective in relieving symptoms, they can also leave patients with permanent side effects such as urinary incontinence, erectile dysfunction and retrograde ejaculation.
NeoTract’s FDA-cleared UroLift System is a novel, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function. Patients also experienced a significant improvement in quality of life. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The UroLift System is available in the U.S., Europe, Australia, Canada, Mexico and South Korea.
A Minimally Invasive BPH Treatment
The simple UroLift System treatment typically performed in less than 15 minutes that uses tiny implants to hold open the obstructed pathway that’s blocking urine flow, addressing the blockage, not just continuously treating enlarged prostate (BPH) symptoms. Most patients return home immediately and experience a speedy recovery. A catheter might be needed for less than 24 hours.
Why the UroLift System?
The UroLift System provides a proven treatment that can get men off BPH medications which can make a person feel foggy and cause sexual dysfunction.1,2 Treatment with the UroLift System has a risk profile better than surgical procedures that may have serious complications and a long, painful recovery.2-5 The treatment may be right for you if any of the following apply:
Learn more about the UroLift Procedure
Sources
1. Roehrborn et al. Can J Urol 2017
2. AUA Guidelines 2003
3. Wasson, Perspectives in Nursing 2000
4. NIH U.S. National Library of Medicine – TURP patient instructions https://medlineplus.gov/ency/patientinstructions/000300.htm
5. Sonksen, EU Urol, 2015 BPH6 Study